LARGE CELL NEUROENDOCRINE CARCINOMA OF THE LUNG
Clinical trials for LARGE CELL NEUROENDOCRINE CARCINOMA OF THE LUNG explained in plain language.
Never miss a new study
Get alerted when new LARGE CELL NEUROENDOCRINE CARCINOMA OF THE LUNG trials appear
Sign up with your email to follow new studies for LARGE CELL NEUROENDOCRINE CARCINOMA OF THE LUNG, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug aims to shrink Hard-to-Treat lung cancers
Disease control Recruiting nowThis phase 2 trial tests BI 764532 (obrixtamig), an antibody-like drug designed to help the immune system attack cancer cells. It is for adults with advanced small cell lung cancer or other neuroendocrine cancers that have not responded to prior treatments. The study compares two…
Matched conditions: LARGE CELL NEUROENDOCRINE CARCINOMA OF THE LUNG
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Experimental combo therapy targets multiple cancers in new trial
Disease control Recruiting nowThis study tests whether adding the drug tarlatamab to standard radiation therapy is safe for people with cancers that have a protein called DLL3, including melanoma, lung cancer, and glioblastoma. About 30 adults with advanced or returning cancers will receive tarlatamab infusio…
Matched conditions: LARGE CELL NEUROENDOCRINE CARCINOMA OF THE LUNG
Phase: PHASE1, PHASE2 • Sponsor: University of Arizona • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New radioactive drug targets tough cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new radioactive drug, 225Ac-ETN029, in 116 adults with advanced DLL3-positive cancers like small cell lung cancer or neuroendocrine tumors. The main goal is to check safety and find the right dose, while also seeing if the drug can shrink tumors. Pa…
Matched conditions: LARGE CELL NEUROENDOCRINE CARCINOMA OF THE LUNG
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New antibody drug targets Hard-to-Treat neuroendocrine cancers
Disease control Recruiting nowThis study tests a new drug, peluntamig (PT217), in people with advanced neuroendocrine cancers like small cell lung cancer. The drug is designed to attach to two proteins (DLL3 and CD47) found on cancer cells, potentially helping the immune system attack them. The trial will fir…
Matched conditions: LARGE CELL NEUROENDOCRINE CARCINOMA OF THE LUNG
Phase: PHASE1, PHASE2 • Sponsor: Phanes Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC